Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia
Leukemia, 05/30/2012Swords R et al.
The authors conclude that multitargeted FMS–like tyrosine kinase receptor–3 (FLT3) inhibitors may have more utility earlier in the course of disease, when in vitro evidence suggests that Acute myeloid leukemia (AML) cells are less dependent on FLT3 signaling, perhaps because of upregulation of multiple other signaling pathways. More potent agents may have greater utility in relapsed and heavily pretreated patients, in whom high levels of circulating FLT3 ligand may necessitate use of an agent with a very favorable pharmacokinetic/pharmacodynamic profile. Novel combination regimens are also discussed.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.